Dermatology – Page 2

First in Human Phase 2 Trial of Zabalafin (AB- 101): A Novel Topical Drug Candidate for Mild, Moderate and Severe Atopic Dermatitis in Children and Adults – Itch and Quality of Life Interim Results

This trial result was presented at the 33rd EADV Congress at Amsterdam by Drs Neal Koller, Gary Pekoe et al from the University of Sydney,

Improvement in Anxiety and Depression in Adult Patients with Severe Alopecia Areata Treated with Deuruxolitinib: Pooled Data from the THRIVE-AA1 and THRIVE-AA2 Phase 3 Trials

This trial results was presented at the 33rd EADV Congress at Amsterdam by Drs Arash Mostaghimi, Brett King, Maryanne M. Senna et al from the

Chemabrasion: Treatment of Difficult Acne and Acne Scarring

This study was presented at the 33rd EADV Congress at Amsterdam by Dr Iftikhar Sheikh from Alhamd Skin Clinics Lahore Pakistan. A recent study has

Beyond the Surface: Exploring the Pathogenesis and Management of Melasma

At the last day of the 33rd EADV Congress 2024, leading experts gathered to discuss the latest findings on melasma and hyperpigmentation, shedding light on

New Guidance, Spironolactone Use, and Recommendations Treating and Preventing Scarring and Hyperpigmentation in Acne

At the 33rd EADV Congress held in Amsterdam, leading experts gathered to discuss the latest developments in acne treatment, focusing on new guidelines, the use

Outcomes of Down- Titration in Patients with Severe Alopecia Areata Treated with Baricitinib: An Update Through Week 152 from BRAVE-AA2

This trial was presented at the 33rd EADV Congress at Amsterdam by Drs Brett King et al from Yale School of Medicine, New Haven, CT,

Efficacy, Tolerability, and Acceptability of a 2.6% Benzoyl Peroxide Acne Cleanser Specifically Designed for Sensitive Skin

This study was presented at the 33rd EADV Congress at Amsterdam by Drs James Q. Del Rosso, Thu Nguyen, and Krzysztof Piotrowski et al from

Innovative Treatment of Active Acne Vulgaris by Chemical Peeling Using TCA 35% and 88% Lactic Acid

This study was presented at the 33rd EADV Congress at Amsterdam by Drs Haider Al- Sabak, Khalifa Edeid Sharquie Al-Sharquie et al from the Faculty

Multimodal Assessments of the Treatment Response of Guselkumab in Mild Psoriasis Patients, An Exploratory Randomized Placebo- Controlled Clinical Trial

This trial result was presented at the 33rd EADV Congress 2024 in Amsterdam, by Drs Menthe Bergmans, Jannik Rouse, Tessa van der Kolk et al

Efficacy and Safety of Orismilast, A potent PDE4B/D Inhibitor, in Adults with Moderate- To-Severe Atopic Dermatitis: A Phase 2b Randomized, Double- Blinded, Placebo- Controlled Clinical Trial (ADESOS)

This trial results were presented at the 33rd EADV Congress 2024 in Amsterdam, by Drs Jonathan I. Silverberg, Lawrence Eichenfield, Andrew Blauvelt et al from